Thymosin Alpha-1 (TA1) Dosage Guide: Protocols, Calculator & Safety
Everything you need to know about Thymosin Alpha-1 (TA1) dosing — protocols, safety, and where to buy.
Dose Range
1,600 mcg (1.6 mg) per injection (standard clinical dose)
Frequency
2–3 times per week subcutaneous
Cycle Length
4–12 weeks; can be used long-term for immune support
Half-Life
~2 hours
Administration Routes
Quick Reconstitution Calculator
Calculate syringe units instantly
Syringe Draw
10.0 units
2500 mcg/ml · 0.100 ml draw
Dosing Protocols
Context: Tα1 is typically used for specific indications rather than general daily supplementation, though long-term twice-weekly regimens are common in aging and chronic illness contexts.
Reconstitution: A 10 mg Tα1 vial reconstituted with 2 mL bacteriostatic water yields 5 mg/mL. On a U-100 insulin syringe: 1 unit (0.01 mL) = 50 μg, 4 units = 200 μg, 10 units = 500 μg, 20 units = 1 mg, 30 units = 1.5 mg.
Protocol A: Standard Immune Support (Most Common Off-Label Use)
For general immune support in aging, post-viral recovery, or as maintenance:
- Dose: 1.6 mg subcutaneous twice weekly (e.g., Monday and Thursday), matching the approved Zadaxin schedule
- Duration: 8-12 week courses, followed by a 4-week break; can be repeated quarterly
- Timing: Morning or evening dose; the 3-4 day interval between doses is more important than time of day
- Injection site: abdomen, flank, thigh; rotate sites
Protocol B: Daily Dosing for Acute Support
For post-infection recovery, long COVID, or intensive immune support contexts:
- Dose: 900 μg subcutaneous daily for 4-8 weeks
- Timing: morning dosing preferred
- Transition: after 4-8 weeks daily, transition to twice-weekly 1.6 mg maintenance or discontinue if acute context has resolved
Protocol C: Vaccine Response Enhancement
For immunocompromised patients around vaccination:
- Dose: 1.6 mg subcutaneous twice weekly
- Timing: starting 2 weeks before planned vaccination, continuing 4 weeks after
- Indication examples: flu vaccination in elderly or dialysis patients; hepatitis B vaccination in non-responders
Protocol D: Athletic Support During Heavy Training Cycles
For athletes with high training load causing documented immune suppression (recurrent URIs, low salivary IgA, etc.):
- Dose: 1.6 mg subcutaneous twice weekly during peak training block
- Duration: cycle-specific, typically 8-12 weeks during intensified preparation
- Discontinuation: at end of competitive period or during tapering
What to Expect: Tα1's effects are typically subtle and measured over weeks rather than felt acutely. Most users do not experience noticeable immediate effects from individual doses. What improves over 4-8 weeks of dosing:
- Fewer and shorter respiratory infections (observational)
- Improved energy in post-viral recovery (subjective)
- Reduced frequency of chronic symptom flares
- Laboratory changes: improved CD4/CD8 ratio, increased lymphocyte counts if baseline was low, improved response to vaccination if tested
Monitoring (optional but recommended for longer courses):
- Baseline labs: CBC with differential, CD4/CD8 ratio, natural killer cell function, CRP, ferritin, 25-hydroxyvitamin D
- Follow-up at 8-12 weeks: repeat CBC and CD4/CD8 if clinically relevant
- For chronic hepatitis B or C (supervised use): viral load and liver function panel
Safety Considerations for Beginners:
- Start at standard dose rather than high dose — Tα1 does not have a clear dose-response benefit beyond the standard regimens
- Use in contexts where immune support is specifically valuable rather than as a general wellness add-on without clear goal
- If any autoimmune condition is present, discuss with rheumatologist before starting
- Inject slowly and rotate sites to minimize local reactions
For users who have completed a beginner cycle and want to optimize.
Extended Duration Regimens: Some chronic conditions benefit from longer Tα1 courses than the standard 8-12 weeks:
- Chronic hepatitis B (supervised): 6-12 months at 1.6 mg twice weekly
- Long COVID with immune dysregulation: some clinical protocols use 3-6 month courses at daily 900 μg or twice-weekly 1.6 mg
- Aging immunity support: quarterly 8-week courses with breaks, continued indefinitely
Dose Optimization: The standard 1.6 mg twice weekly or 900 μg daily should be considered the starting point. Some protocols use higher frequency (daily at 1.6 mg) during acute illness or intensive recovery, then taper to standard maintenance. Higher dose per injection does not clearly add benefit.
Tracking Individual Response: Beyond clinical symptom improvement, consider lab-based tracking:
- Basic: CBC with differential showing lymphocyte count trends
- Intermediate: CD4/CD8 ratio, CD4 count, CD8 count, natural killer cell percentages
- Advanced: T-cell exhaustion markers (PD-1, TIM-3), cytokine panels (IL-6, TNF-α, IFN-γ), antibody response to vaccines
- Symptom tracking: structured log of infections, recovery time, baseline energy, chronic symptom flares
Combination Refinement:
- Tα1 + BPC-157 + TB-500 triple protocol: Tα1 twice weekly, BPC-157 250 μg BID, TB-500 2-2.5 mg twice weekly. Popular comprehensive wellness stack.
- Tα1 + GH-axis peptides during recovery phases: immunocompetence + tissue repair + recovery support
- Tα1 + LL-37 for chronic infection contexts: host immunity + direct antimicrobial coverage
Timing With Infections: For users using Tα1 prophylactically during high-exposure periods (travel, family illness, seasonal epidemics):
- Start 2-4 weeks before planned exposure if possible
- Continue through exposure period
- If infection occurs despite prophylaxis, consider increasing frequency to daily during acute illness
Troubleshooting Non-Response:
- Ensure product quality (reputable vendor with CoA; Zadaxin or compounded-from-Zadaxin-equivalent preferred over grey-market)
- Assess baseline deficits — vitamin D, zinc, sleep, nutrition are often the actual limiting factors
- Consider whether indication matches Tα1's mechanism — Tα1 is not effective for all immune problems; primary autoimmunity or allergic disease may not benefit
- Longer course before declaring non-response (full 12 weeks)
Long-Term Use Considerations:
- No clear adaptation or tolerance documented in long-term studies
- Cycling (8 weeks on, 4 weeks off) is common but may not be necessary
- Continuous low-dose maintenance (twice weekly 1.6 mg) appears safe in chronic illness populations over months to years
- Regular lab monitoring (quarterly to semi-annually) supports rational dose adjustment
Still Recommended:
- Optimize non-peptide foundations first (sleep, nutrition, micronutrient sufficiency)
- Work with a functional medicine or integrative medicine clinician whenever possible for longer protocols
- Document response objectively; subjective improvement alone can be confounded by placebo and regression to mean in chronic illness contexts
For experienced users with specific chronic conditions or complex clinical scenarios, ideally under clinician supervision.
Scenario 1: Long COVID / Post-Viral Syndrome Complex
Tα1 is increasingly used in long COVID protocols. Advanced considerations:
- Characterize baseline immune dysfunction with extended panels (lymphocyte subsets, cytokines, EBV/HHV-6 reactivation, autoantibodies)
- Stack with complementary agents: LDN, NAC, methylene blue (in select cases), mitochondrial support
- Longer courses (3-6 months) with dose adjustment based on response
- Realistic expectations: Tα1 is not a cure for long COVID; it supports immune function alongside other interventions
Scenario 2: Chronic Viral Infection (EBV Reactivation, HHV-6, CMV)
Suspected chronic viral reactivation in CFS/ME-like presentations:
- Consider lab-documented viral activity (viral capsid IgM, PCR if available)
- Tα1 1.6 mg twice weekly for 3-6 months alongside any specific antivirals used
- Monitor for both clinical symptom improvement and viral marker trends
- Layered approach with immune support, antivirals, and lifestyle factors
Scenario 3: Cancer Immunotherapy Adjunctive (Oncologist-Supervised Only)
Absolutely requires oncology direction:
- Potential stacking with checkpoint inhibitors is an active research area
- Dose and timing must be coordinated with primary immunotherapy
- Never self-directed; work with integrative oncology clinicians aware of Tα1 research
Scenario 4: Aging Immunity in Centenarian-Seeking Protocols
For advanced longevity-oriented users:
- Tα1 twice weekly as ongoing maintenance in users with documented age-related immune decline
- Stacked with other longevity peptides (Epithalon, thymulin analogs where available)
- Regular labs to document response; absence of lab improvement may argue against continuing
- Realistic framing: no clinical evidence that Tα1 extends life in healthy individuals; mechanistic rationale for immune support in aging is separate from longevity claims
Scenario 5: Heavy Training / Elite Athletic Preparation
Elite athletes with documented exercise-induced immunosuppression:
- Tα1 twice weekly during peak training blocks
- Cycle off during rest/tapering phases
- Sports drug-testing considerations: Tα1 is not explicitly prohibited by WADA but is on some monitored lists; check current status before use in competitive athletes
- Document baseline and response with salivary IgA, CBC, and infection-rate tracking
Advanced Combinations:
- Tα1 + IL-2 (low dose): experimental; not routine
- Tα1 + CpG oligonucleotides: synergistic TLR9 agonism, research use only
- Tα1 + peptide-based vaccines: research use in cancer immunotherapy
Advanced Cautions:
- Long-term continuous use (>1 year) is uncharacterized in large studies
- Cost can become significant with extended protocols
- Diminishing returns: if 3-6 months has not produced clear benefit, reassess rather than continuing indefinitely
- Any concerning autoimmune symptoms during use warrant immediate evaluation
When to Discontinue:
- Clear clinical resolution of the target condition
- Lack of benefit after adequate trial
- Emergence of autoimmune-like symptoms
- Development of any cancer (reassess risk-benefit with oncology)
- Pregnancy or breastfeeding
- Organ transplantation
Medical Supervision: Tα1 for chronic use or complex indications strongly benefits from clinician supervision — ideally someone familiar with peptide pharmacology and the user's specific condition. Functional medicine and integrative medicine practices are common starting points for finding clinician support.
Weight-Based Dosing
Commonly Stacked With
Tα1 is a commonly stacked peptide in comprehensive regimens, as its immune-modulating effects complement rather than duplicate most other peptide actions.
Tα1 with BPC-157 and TB-500: The most common wellness-oriented peptide stack combines immune modulation (Tα1), tissue repair/vascular protection (BPC-157), and actin-regulation/healing (TB-500). These three operate through completely independent mechanisms with no known pharmacological interactions. Common patterns: Tα1 twice weekly, BPC-157 daily or BID, TB-500 twice weekly. The combined stack supports immune function alongside general recovery and healing. Users in recovery from chronic illness, post-surgical recovery, or extensive training loads commonly use this triple.
Tα1 with Epithalon: Both positioned as longevity-oriented peptides but with different mechanisms — Tα1 modulates immune function while Epithalon's proposed mechanism involves telomerase activation and pineal regulation. Stacking is commonly used in anti-aging contexts without known interaction.
Tα1 with LL-37: Different mechanisms — Tα1 modulates host immunity; LL-37 is a cathelicidin antimicrobial peptide with direct antimicrobial activity against bacteria and some viruses. The two can be complementary in chronic infection contexts (LL-37 for direct antimicrobial effect, Tα1 for host immune response enhancement). No known interaction.
Tα1 with Ipamorelin, CJC-1295, or Tesamorelin: GH-axis peptides and Tα1 operate through completely independent pathways. Some users stack for recovery + immunity goals. No known interaction.
Tα1 with Oxytocin, PT-141, or Kisspeptin-10: Unrelated pharmacology; no interaction concerns.
Tα1 during COVID-19 or Long COVID Protocols: Tα1 is frequently part of clinician-directed long COVID protocols, often combined with:
- Low-dose naltrexone (LDN) for immune modulation and fatigue
- N-acetylcysteine (NAC) for glutathione support
- CoQ10, alpha-lipoic acid for mitochondrial support
- Vitamin D, zinc, vitamin C at reasonable doses
- Occasionally BPC-157 for vascular and GI effects
Tα1 During Cancer Adjunctive Therapy: Must be done only under oncology supervision. Potential stacking with checkpoint inhibitors (pembrolizumab, nivolumab) is an active research area — theoretically synergistic but not yet established as standard practice. Tα1 with traditional chemotherapy has been used adjunctively in some protocols.
Tα1 During Heavy Training / Athletic Cycles: Athletes sometimes stack Tα1 with:
- Growth-hormone-axis peptides for recovery
- BPC-157 for tissue repair
- Adaptogenic herbs (ashwagandha, rhodiola) for stress resilience
- Magnesium, zinc, vitamin D for baseline immune support
Avoid Combining With:
- Immunosuppressive therapy for autoimmunity (methotrexate, cyclosporine, tacrolimus, biologics like infliximab or rituximab) — Tα1's immune activation may counteract therapeutic goals. Discuss with rheumatologist before combining.
- Calcineurin inhibitors for transplant maintenance — absolute contraindication unless under transplant-center supervision.
- High-dose corticosteroids for acute inflammation — may neutralize Tα1 effects; pharmacologically opposed.
Timing Considerations When Stacking:
- Tα1 can be injected in the same injection session as other subcutaneous peptides (different injection sites) with no pharmacokinetic interaction.
- Daily Tα1 users often inject morning; those on twice-weekly protocols typically dose with consistent 3-4 day intervals.
- No reported interactions with time-of-day timing of other peptides.
Non-Peptide Supporting Factors for Immune Function:
- Adequate sleep — chronic sleep deprivation blunts immune response regardless of peptide support
- Adequate protein intake — immune cells require amino acid precursors
- Vitamin D sufficiency (25-OH-D > 40 ng/mL) — strongly supports immune response to infection
- Zinc adequacy — supports T-cell function and is depleted with chronic infection or stress
- Omega-3 fatty acids for inflammation modulation
- Mediterranean-style eating patterns reduce chronic inflammation
Side Effects & Safety
Contraindications
**Absolute contraindications:** - Organ transplant recipients on maintenance immunosuppression (Tα1's immune activation could trigger rejection) - Active hypersensitivity to Tα1 preparations - Pregnancy (no adequate safety data) - Breastfeeding (no data) - Acute hyperinflammatory states (severe cytokine storm, uncontrolled sepsis in late phase) — requires specialist assessment **Strong relative contraindications:** - Poorly controlled autoimmune disease (lupus, rheumatoid arthritis, multiple sclerosis, Hashimoto's thyroiditis with significant inflammation) — risk of flare; only use under rheumatology/specialist supervision - Recent organ transplantation - Active hematologic malignancy (requires oncology direction) - Concurrent high-dose systemic corticosteroid therapy (pharmacologically opposed effect; limited benefit) - Concurrent cytotoxic chemotherapy (effects may be altered; coordination with oncology essential) **Drug interactions:** - **Immunosuppressants (methotrexate, azathioprine, cyclosporine, tacrolimus, biologics):** Pharmacologic antagonism; discuss with prescribing physician before combining. - **High-dose corticosteroids (chronic prednisone >20 mg/day):** May neutralize Tα1 effects; pharmacologic antagonism. - **Cytotoxic chemotherapy:** Complex interactions; only under oncology direction. - **Interferon preparations:** Generally synergistic (standard use in hepatitis), but monitor cytokine-related side effects. - **Checkpoint inhibitors (nivolumab, pembrolizumab):** Potentially synergistic (active research); discuss with oncology. - **Live attenuated vaccines:** Tα1 may improve vaccine response (potentially useful) but also theoretically increase risk of vaccine-derived adverse events in immunocompromised patients; discuss with prescribing clinician. **Stop using if:** - Signs of allergic reaction (hives, facial swelling, difficulty breathing) - Severe injection site reaction persistent beyond 48 hours - Unexplained worsening of an underlying autoimmune condition - Development of new autoimmune symptoms (unexplained joint pain, rashes, fatigue patterns) - Signs of organ transplant rejection (if inadvertently used) - Pregnancy (confirmed or suspected) - New cancer diagnosis (reassess with oncology) **Monitoring:** - **Baseline (recommended before longer courses):** CBC with differential, CD4/CD8 ratio, complete metabolic panel, CRP, 25-OH vitamin D, ferritin. Consider viral serologies if chronic infection suspected. - **During therapy:** symptom tracking; repeat CBC and CD4/CD8 at 8-12 weeks if clinically relevant - **End of course:** repeat relevant labs to document response - **For autoimmunity patients:** ANA, specific auto-antibodies at baseline and if new symptoms develop **Special Caution Scenarios:** - Users on multiple peptide protocols should layer in Tα1 after establishing baseline responses to other peptides; sudden addition of multiple immune-modulating compounds complicates adverse-event attribution - Users with vague chronic illness should consider full workup before multi-month Tα1 protocols; some underlying conditions (malignancy, structural problems) benefit from early direct treatment rather than immune modulation - In competitive athletes: verify current WADA / sport-specific drug testing status; Tα1 is not explicitly prohibited but has been discussed in monitoring contexts **Medical Supervision:** Tα1 benefits significantly from clinician supervision for anything beyond short-term basic use. Chronic viral infection, long COVID, cancer-adjunctive contexts, and autoimmune-adjacent conditions all benefit from professional oversight. Functional medicine and integrative medicine practices are common sources of support for Tα1-inclusive protocols.
Additional Notes
Standard dose ranges across indications:
- Twice-weekly standard: 1.6 mg subcutaneous twice weekly (Zadaxin-approved schedule)
- Daily maintenance: 900 μg subcutaneous daily (alternative to twice-weekly)
- Intensive daily for acute contexts: 1.6 mg subcutaneous daily for 4-8 weeks
- Pediatric (rare off-label): requires pediatric specialist; not discussed in this adult-focused guide
Reconstitution specifics:
-
10 mg vial + 2 mL BAC water → 5 mg/mL. On insulin syringe: 1 unit = 50 μg.
- 20 units = 1 mg
- 32 units = 1.6 mg (standard dose)
- 18 units = 900 μg (daily alternative)
-
10 mg vial + 1 mL BAC water → 10 mg/mL. On insulin syringe: 1 unit = 100 μg.
- 9 units = 900 μg
- 16 units = 1.6 mg
- 100 units (1 mL) = 10 mg (full vial)
Storage:
- Lyophilized Tα1: refrigerate 2-8°C or freeze; stable 24+ months sealed
- Reconstituted Tα1: refrigerate only at 2-8°C; stable 4-6 weeks after reconstitution
- Do not freeze reconstituted peptide
- Protect from light
Injection Technique:
- Subcutaneous; 29-31G x 5/16" insulin needle
- Abdomen, flanks, outer thighs rotation
- Inject slowly over 2-3 seconds
- Standard SC technique; aspiration not needed with short needles
Timing:
- Day-of-week consistency matters more than time-of-day
- Morning dosing often preferred for twice-weekly regimens
- Daily dosing: morning for consistency; no specific time-of-day pharmacokinetic benefit
- Food timing does not affect SC Tα1 pharmacokinetics
Common Dosing Mistakes:
- Expecting dramatic acute effects — Tα1 benefits accrue over weeks
- Over-frequent dosing (three+ times weekly at 1.6 mg) without clear indication — wastes peptide without added benefit
- Under-dosing at 500 μg or less (unless specifically indicated) — may not reach effective tissue concentration
- Using Tα1 for acute flu-like illness hoping for antiviral effect — it is not directly antiviral and is more effective as immune support over days to weeks, not hours
- Stopping after 2-3 weeks without response — needs 6-12 week trial for most indications
- Using during active corticosteroid therapy — pharmacologically opposed
- Using in transplant recipients without specialist approval
Upper Limit for Typical Off-Label Use: Doses above 1.6 mg per injection are not standard and do not have clear dose-response benefit. Daily 1.6 mg is the upper routine frequency; higher cumulative exposure is uncharacterized.
Special Populations:
- Elderly: standard doses appropriate; possibly longer courses beneficial
- Dialysis patients: standard doses; Tα1 clearance may be altered but no dose adjustment typically required
- Severe hepatic dysfunction: clearance possibly altered; consider reducing frequency
- Pediatric: requires pediatric specialist; this guide is adult-focused
Product Quality Considerations: Tα1 is relatively stable and synthesizable by standard peptide methods, but product quality among peptide vendors varies. Higher-quality sources:
- Brand-name Zadaxin (where available, expensive)
- Compounding pharmacies producing pharmaceutical-grade Tα1
- Established peptide vendors with batch CoAs showing HPLC purity >95%
Grey-market unverified products are of uncertain actual peptide content and purity.
Where to Buy Thymosin Alpha-1 (TA1)
Compare 5 listings across 4 vendors — from $39.99
Frequently Asked Questions
What is the recommended Thymosin Alpha-1 (TA1) dosage?
The typical dose range for Thymosin Alpha-1 (TA1) is 1,600 mcg (1.6 mg) per injection (standard clinical dose). It is usually administered 2–3 times per week subcutaneous. Always start with the lowest effective dose.
How often should I take Thymosin Alpha-1 (TA1)?
2–3 times per week subcutaneous
Does Thymosin Alpha-1 (TA1) need to be cycled?
Yes, typical cycle length is 4–12 weeks; can be used long-term for immune support.
What are Thymosin Alpha-1 (TA1) side effects?
Tα1 has one of the most benign side-effect profiles in the peptide space, supported by 45+ years of clinical experience in approved indications. Most users experience no acute side effects beyond mild injection site discomfort. **Common (5-15% of users):** - **Injection site reactions** — mild redness, transient soreness, occasional small bruise. Minimal with proper subcutaneous technique. - **Transient mild fatigue or malaise** — in the first week of dosing, some users report mild flu-like feelings reflecting immune activation. Usually resolves within days. - **Mild transient headache** — uncommon and self-resolving. **Uncommon but Reported:** - **Localized rash at injection site** — rare; usually resolves with site rotation. - **Mild elevation in liver enzymes** — sporadically reported in chronic hepatitis patients, reflecting immune activity against infected hepatocytes rather than toxicity. Usually clinically insignificant. - **Temporary worsening of symptoms in chronic inflammatory conditions** — some users with autoimmune conditions report transient flares of symptoms during initial Tα1 dosing, reflecting immune reactivation. Discuss with a clinician if suspected. - **Mild lymphocyte count elevation** — expected pharmacological effect rather than adverse event; reflects immune activation. - **Rare reports of mild mood changes** — usually mild; cytokine-mediated. **Rare but Serious:** - **Hypersensitivity reactions** — very rare; includes rash, hives, rarely anaphylaxis with repeated dosing in sensitized individuals. - **Autoimmune exacerbation** — theoretical risk, very rarely documented. In users with preexisting autoimmune conditions (lupus, rheumatoid arthritis, multiple sclerosis), Tα1's immune modulation could theoretically worsen rather than stabilize disease. Clinical evidence of this happening is scarce but caution is warranted. - **Cytokine imbalance in severely ill patients** — in sepsis and severe COVID-19, Tα1's effects depend on disease stage; early dosing appears beneficial, but aggressive dosing in late-stage cytokine-storm states may not help or may theoretically worsen hyperinflammation. This is a concern in inpatient intensive care rather than outpatient off-label use. **Theoretical Concerns:** - **Pregnancy:** no adequate safety data; avoid unless specifically indicated. - **Breastfeeding:** no data; avoid unless specifically indicated. - **Organ transplant recipients:** Tα1's immune-enhancing effects could theoretically interfere with transplant-maintenance immunosuppression. Absolute contraindication without transplant-center supervision. - **Active autoimmune disease:** theoretical risk of disease flare; use with autoimmunity-literate physician supervision. **Who Should Exercise Particular Caution:** - Users with poorly controlled autoimmune disease - Organ transplant recipients (absolute contraindication without specialist supervision) - Users with known hypersensitivity to Tα1 preparations - Pregnant or breastfeeding women - Users on immunosuppressive therapy for autoimmunity (methotrexate, biologics) — discuss with treating rheumatologist before starting - Users with hematologic malignancies where immune modulation could affect treatment response **What Is NOT a Reported Safety Concern With Tα1:** - Hepatotoxicity - Nephrotoxicity (at typical doses) - Cardiovascular events - Neurotoxicity - Genotoxicity or carcinogenicity (opposite — used as cancer-adjunctive in some settings) - Endocrine disruption - Dependence or withdrawal **Compared to Other Immune-Oriented Peptides:** - Tα1 has a cleaner safety profile than cytokines (IL-2, IFN-α) which cause flu-like syndromes and dose-limiting toxicity - Tα1 is safer than broad immunomodulators (corticosteroids, calcineurin inhibitors) for long-term use - Tα1 safety profile is comparable to [BPC-157](/compound/bpc-157) and [TB-500](/compound/tb-500) — all three are among the safest peptides in common use Overall Tα1 sits at the favorable end of the peptide safety spectrum, making it appropriate for relatively long-term use in appropriate populations — a significant advantage when chronic immune support is the goal.
Where can I buy Thymosin Alpha-1 (TA1)?
Compare 5 listings from 4 vendors on our price comparison page — starting from $39.99.
Free 2026 Peptide Cheat Sheet — 50 pages, PDF
Dosing, reconstitution, stacks, half-lives, and vendor trust tiers. The reference we wish we had on day one.